South Korea Biopharmaceutical CMO And CRO Market Insight
Published: 16 June 2026 | Report Format: Electronic (PDF)
The South Korea biopharmaceutical cmo and cro market is expected to grow at a CAGR of around 11.9% owing to rising biologics production, increasing outsourcing by pharmaceutical companies, expanding clinical research activities, strong government support.
South Korea Biopharmaceutical CMO And CRO Market Insight Forecasts to 2035
- The South Korea Biopharmaceutical CMO & CRO Market Size was estimated at USD 4.8 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.9% from 2025 to 2035
- The South Korea Biopharmaceutical CMO & CRO Market Size is Expected to Reach USD 14.9 Billion by 2035
Notable Insights for the South Korea Biopharmaceutical CMO And CRO Market
- Based on the Segmentation by Service Type, Contract Manufacturing Organization (CMO) Services segment is leading the South Korea Biopharmaceutical CMO & CRO Market in 2025, holding nearly 58% market share due to increasing biologics manufacturing outsourcing.
- Based on the Segmentation by Molecule Type, it can be seen that the Biologics & Biosimilars segment accounted for approximately 63% market share in 2025, mainly driven by expanding biosimilar development programs, increasing biologic drug approvals.
- The global revenue of Samsung Biologics Co., Ltd. in fiscal year 2025 stood at nearly USD 3.5 billion, supported by growing demand for contract development, biologics manufacturing services.
- Increasing investments in cell and gene therapies, biopharmaceutical innovation, improve production efficiency by nearly 40% while reducing development timelines by approximately 30%.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
• Intelligent Market Research Based on AI for Healthcare & Biopharmaceutical Services
Decisions Advisors provides intelligent market research covering biopharmaceutical contract manufacturing, clinical research outsourcing, biologics development, biosimilars production, and advanced therapy manufacturing. The research identifies emerging opportunities, investment trends, competitive positioning, technological advancements, and strategic developments shaping the South Korea Biopharmaceutical CMO & CRO Market.
• Highly Effective Research Approaches with Accurate Forecast Analysis
The research methodology incorporates primary interviews, pharmaceutical industry analysis, healthcare value-chain tracking, and data triangulation techniques to deliver accurate market sizing, growth forecasting, investment assessment, and technology trend evaluation. The study analyzes demand across biologics manufacturing, clinical development, regulatory services, and commercial biopharmaceutical production sectors.
• Highly Competitive Environment Analysis
The report provides comprehensive analysis of leading biopharmaceutical outsourcing companies, manufacturing innovations, clinical research capabilities, strategic collaborations, facility expansions, and regulatory developments. It further evaluates R&D investments, capacity expansion strategies, and emerging opportunities within the South Korea Biopharmaceutical CMO & CRO Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Biopharmaceutical CMO And CRO Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Biopharmaceutical CMO And CRO Market
- Samsung Biologics Co., Ltd.
- Celltrion Inc.
- SK Bioscience Co., Ltd.
- Lotte Biologics Co., Ltd.
- CHA Biotech Co., Ltd.
- LG Chem Life Sciences
- GC Biopharma
- DreamCIS Inc.
- Novotech
- Parexel International Corporation
Recent Developments:
• In October 2025, Samsung Biologics Co., Ltd. announced the expansion of its biologics manufacturing capacity to support increasing global demand for monoclonal antibodies, biosimilars, and innovative biologic therapies.
• In June 2025, Lotte Biologics Co., Ltd. expanded its contract development and manufacturing capabilities through investments in advanced bioprocessing infrastructure and next-generation biologics production technologies.
Market Segmentation:
South Korea Biopharmaceutical CMO And CRO Market, By Service Type
- Contract Manufacturing Organization (CMO)
- Contract Research Organization (CRO)
- Contract Development & Manufacturing Organization (CDMO)
- Clinical Trial Services
- Regulatory & Consulting Services
South Korea Biopharmaceutical CMO And CRO Market, By Molecule Type
- Biologics
- Biosimilars
- Cell & Gene Therapies
- Vaccines
- Recombinant Proteins
South Korea Biopharmaceutical CMO And CRO Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Academic & Research Institutes
- Medical Device Companies
- Government Research Organizations
Expert Views:
The South Korea Biopharmaceutical CMO And CRO Market is expected to witness robust growth driven by increasing biologics outsourcing, expanding biosimilar development, and rising investments in advanced biomanufacturing facilities. Strong government support, growing clinical research activities, and adoption of innovative cell and gene therapy technologies will further strengthen market demand. Strategic collaborations between global pharmaceutical companies and South Korean service providers are anticipated to enhance manufacturing capacity, improve development efficiency, and accelerate commercialization of next-generation biopharmaceutical products through 2035.
Author: Govind and Krishna By Decisions Advisors and Consulting